The Evolution of Atopic Dermatitis Care: Bridging the Gap Between Guidelines and Clinical Practice

Track 1 Overview

This interactive activity will feature branching modules that simulate real-world scenarios while providing learners with detailed, immediate feedback. Participants will engage in education that simulates treating atopic dermatitis and utilizing a SDM approach to better coordinate care among specialties for patients.

TARGET AUDIENCE

This activity is designed to educate community-based HCPs involved in the care of patients with moderate-to-severe atopic dermatitis, including Specialists (e.g., (1) Dermatologists, (2) Allergists, (3) Primary Care Physicians, (4) Pediatricians, (5) Pharmacists, (6) NPs and PAs.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

• Describe factors that contribute to AD disease burden and poor QoL, including challenges with topical therapy.
• Assess the role of IL-13 in the pathophysiology of AD as well as the mechanisms, efficacy, and safety for IL-13 targeted therapies.
• Summarize treatment initiation, selection, and intensification strategies, as well as how to utilize a treat-to-target approach in clinical practice.

JOINT ACCREDITATION STATEMENT

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of .50 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSES (ANCC) CREDIT DESIGNATION

Med Learning Group designates this activity for a maximum of .50 ANCC contact hours.

ACCME INNOVATION PARTNER DISCLAIMER

Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)

All relevant financial relationships have been mitigated.

Content Review

The content of this activity was independently peer reviewed by a physician and nurse reviewer.

Individuals in Control of the Content of the Activity

The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:

• Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
• Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
• Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
• Shannon Mutch MS, RN, OCN, has nothing to disclose.
• M. Susan Burke, MD, has nothing to disclose.
• A medical reviewer from CME Peer Review LLC, has nothing to disclose.
• Vai Deshpande, PhD, Medical Director for Med Learning Group, has nothing to disclose.
• Andi Koral, Program Manager for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CE credit for this activity.

In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.

Your certificate will be provided as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CE questions, please contact Med Learning Group at [email protected]

Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

ACCME INNOVATION PARTNER DISCLAIMER

Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (eg, name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.

RELEASED DATE: February 13, 2026
EXPIRATION DATE: February 13, 2027

Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited

Track 2 Overview

This interactive activity will feature branching modules that simulate real-world scenarios while providing learners with detailed, immediate feedback. Participants will engage in education that simulates treating atopic dermatitis and utilizing a SDM approach to better coordinate care among specialties for patients.

TARGET AUDIENCE

This activity is designed to educate community-based HCPs involved in the care of patients with moderate-to-severe atopic dermatitis, including Specialists (e.g., (1) Dermatologists, (2) Allergists, (3) Primary Care Physicians, (4) Pediatricians, (5) Pharmacists, (6) NPs and PAs.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

• Describe factors that contribute to AD disease burden and poor QoL, including challenges with topical therapy.
• Assess the role of IL-13 in the pathophysiology of AD as well as the mechanisms, efficacy, and safety for IL-13 targeted therapies.
• Summarize treatment initiation, selection, and intensification strategies, as well as how to utilize a treat-to-target approach in clinical practice.

JOINT ACCREDITATION STATEMENT

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of .50 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSES (ANCC) CREDIT DESIGNATION

Med Learning Group designates this activity for a maximum of .50 ANCC contact hours.

ACCME INNOVATION PARTNER DISCLAIMER

Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)

All relevant financial relationships have been mitigated.

Content Review

The content of this activity was independently peer reviewed by a physician and nurse reviewer.

Individuals in Control of the Content of the Activity

The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:

• Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
• Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
• Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
• Shannon Mutch MS, RN, OCN, has nothing to disclose.
• M. Susan Burke, MD, has nothing to disclose.
• A medical reviewer from CME Peer Review LLC, has nothing to disclose.
• Vai Deshpande, PhD, Medical Director for Med Learning Group, has nothing to disclose.
• Andi Koral, Program Manager for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CE questions, please contact Med Learning Group at [email protected]

Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

ACCME INNOVATION PARTNER DISCLAIMER

Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.

RELEASED DATE: February 13, 2026
EXPIRATION DATE: February 13, 2027

Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited

Track 3 Overview

This interactive activity will feature branching modules that simulate real-world scenarios while providing learners with detailed, immediate feedback. Participants will engage in education that simulates treating atopic dermatitis and utilizing a SDM approach to better coordinate care among specialties for patients.

TARGET AUDIENCE

This activity is designed to educate community-based HCPs involved in the care of patients with moderate-to-severe atopic dermatitis, including Specialists (e.g., (1) Dermatologists, (2) Allergists, (3) Primary Care Physicians, (4) Pediatricians, (5) Pharmacists, (6) NPs and PAs.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

• Describe factors that contribute to AD disease burden and poor QoL, including challenges with topical therapy.
• Assess the role of IL-13 in the pathophysiology of AD as well as the mechanisms, efficacy, and safety for IL-13 targeted therapies.
• Summarize treatment initiation, selection, and intensification strategies, as well as how to utilize a treat-to-target approach in clinical practice.

JOINT ACCREDITATION STATEMENT

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of .50 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

NURSES (ANCC) CREDIT DESIGNATION

Med Learning Group designates this activity for a maximum of .50 ANCC contact hours.

ACCME INNOVATION PARTNER DISCLAIMER

Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)

All relevant financial relationships have been mitigated.

Content Review

The content of this activity was independently peer reviewed by a physician and nurse reviewer.

Individuals in Control of the Content of the Activity

The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:

• Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
• Lauren Welch, MA, Sr VP of Operations for Med Learning Group, has nothing to disclose.
• Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
• Shannon Mutch MS, RN, OCN, has nothing to disclose.
• M. Susan Burke, MD, has nothing to disclose.
• A medical reviewer from CME Peer Review LLC, has nothing to disclose.
• Vai Deshpande, PhD, Medical Director for Med Learning Group, has nothing to disclose.
• Andi Koral, Program Manager for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CE questions, please contact Med Learning Group at [email protected]

Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

ACCME INNOVATION PARTNER DISCLAIMER

Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.

RELEASED DATE: February 13, 2026
EXPIRATION DATE: February 13, 2027

Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited